Anti-CD19/CD3ε (Blinatumomab), Bispecific Antibody

Anti-CD19/CD3ε (Blinatumomab), Bispecific Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a bispecific T-cell engager monoclonal antibody that targets both CD19 and CD3ε. A single molecule of this antibody possesses two binding sites: one for CD3ε expressed on T-cells and second for CD19 expressed on B-cells. The antibody forms a synapse between T-cells and malignant B-cells. Upon interaction, T-cells are activated, which release cytotoxic granules such as perforins and granzymes. Granzymes enter the cell cytoplasm with the help of perforins and initiate cell death pathways via activation of caspases. The original antibody has been approved by the FDA to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in both adults and children

Immunogen Sequence:Human CD19/CD3ε

Target Alternative Name:AMG103, BITE MT-103, MEDI-538, MT103, bscCD19xCD3, MEDI 538, MEDI538, MT 103, B4, CVID3, CD19, T3E, TCRE, IMD18, CD3E

Species Reactivities:Human

Tag Line:The biosimilar is a bispecific monoclonal antibody that targets both CD19 on malignant B cells and CD3ε on T-cells and causes caspase-mediated cell death. The original monoclonal antibody is approved to treat acute lymphoblastic leukemia

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.